1
Tamaki Kazuhiko, Yamaguchi Takahiro, Oda Kozo, Terasaka Naoki, Nakai Daisuke, Nakadai Masakazu: (Ja) 2以上の置換基を有するベンゼン化合物, (En) Benzene compound having 2 or more substituents. Daiichi Sankyo Company, Tamaki Kazuhiko, Yamaguchi Takahiro, Oda Kozo, Terasaka Naoki, Nakai Daisuke, Nakadai Masakazu, YAGUCHI Toshiaki, May 4, 2006: WO/2006/046593 (45 worldwide citation)

(EN) Disclosed is an excellent LXR modulator. Specifically disclosed is a compound represented by the general formula (I) below or the like. (I) [In the formula, R1 represents a -COR9 (wherein R9 represents an alkyl, optionally substituted alkoxy or optionally substituted amino); R2 represents an H, ...


2
Terasaka Naoki, Hiroshima Ayano: (Ja) 組織因子産生抑制剤, (En) Tissue factor production inhibitor. Sankyo Company, Terasaka Naoki, Hiroshima Ayano, SIKs 8th Floor Kyobashi Nisshoku Bldg 8 7 Kyobashi 1 chome Chuo ku Tokyo 1040031, January 12, 2006: WO/2006/004030 (5 worldwide citation)

(EN) A pharmaceutical having the potency of inhibiting the production of tissue factors, which pharmaceutical comprises an LXR ligand as an active ingredient. There is provided a pharmaceutical for the treatment and/or prevention of vascular re-stenosis encountered after angioplasty, endarterectomy, ...


3
Tamaki Kazuhiko, Yamaguchi Takahiro, Oda Kozo, Terasaka Naoki, Nakai Daisuke, Nakadai Masakazu: Benzene compound having 2 or more substituents. Daiichi Sankyo, July 11, 2007: EP1806332-A1 (3 worldwide citation)

A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R 1 : -COR 9 (wherein R 9 : alkyl, optionally substituted alkoxy or optionally substituted amino); R 2 : H, OH, alkoxy, optionally substituted amino, etc.; R 3 : H, optionally substituted alkyl, cycloal ...


4
Terasaka Naoki, Hiroshima Ayano: Tissue factor production inhibitor. Sankyo, March 21, 2007: EP1764075-A1 (3 worldwide citation)

A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or s ...


5
Tamaki Kazuhiko, Yamaguchi Takahiro, Terasaka Naoki: (Ja) 置換インドール化合物, (En) Substituted indole compound. Daiichi Sankyo Company, Tamaki Kazuhiko, Yamaguchi Takahiro, Terasaka Naoki, YAGUCHI Toshiaki, October 19, 2006: WO/2006/109633 (2 worldwide citation)

(EN) Disclosed is an excellent LXR modulator. A compound represented by the general formula (I): (I) wherein R1, R2, R3 and R4: H, an alkyl which may be substituted, OH, an alkoxy which may be substituted, an amino which may be substituted, a halogeno, a phenyl or the like; R5: H or an alkyl; R6: -C ...


6

7
Terasaka Naoki, Honzumi Shoko, Schulman Ira Glenn, Wagner Brandee Lynn, Willy Patricia J: Lxr ligand testing method. Daiichi Sankyo, April 9, 2008: EP1907564-A2

A method of easily measuring whether or not an LXR ligand has the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration in a mammal by using the binding activity between LXR and a coactivator, and a method of identifying LXR ligands that do n ...


8

9
Terasaka Naoki, Hiroshima Ayano: Tissue factor production inhibitor. Sankyo, guowen ji liangmou, February 6, 2008: CN200580029545

A pharmaceutical having the potency of inhibiting the production of tissue factors, which pharmaceutical comprises an LXR ligand as an active ingredient. There is provided a pharmaceutical for the treatment and/or prevention of vascular re-stenosis encountered after angioplasty, endarterectomy, perc ...


10